According to a study commissioned by pharmaceutical company Pfizer, the company’s Covid-19 drug Paxlovid cannot prevent the transmission of infections. “While we are disappointed with the outcome of this particular study, these results do not affect the strong efficacy and safety data we observed in our previous study treating patients with Covid-19,” said Albert Bourla, managing director of Pfizer.
The company said the study’s safety data are consistent with previous studies showing that the pills prevent nearly 90% of hospitalization or death in Covid patients at high risk of serious illness.